Lay Title: Successful treatment of STING-associated vasculopathy (SAVI) with bone marrow stem cell transplantation
Title:
Date of publication:
12/5/26
Author:
Roger Brooks
Category:
SAVI Treatment
Article body content:
Plain Language
This paper describes the first known child with a rare genetic inflammatory disease called SAVI (STING-associated vasculopathy with onset in infancy) to be successfully treated with a bone marrow/stem cell transplant from a healthy older sister. The child had severe skin sores, lung disease, repeated infections, and ongoing inflammation that did not improve enough despite treatment with several medications.
After receiving a stem cell transplant, the child’s skin ulcers healed, inflammation settled, lung disease stopped worsening, and overall health and physical activity improved. One temporary complication (autoimmune anaemia) was successfully treated. One year later, the child remained well with stable lung function and improved growth.
The study suggests that stem cell transplantation may offer a possible long-term cure for some children with severe SAVI when standard medicines are not enough.
Why it Matters
This study is important because it provides the first documented successful use of non-self or allo-hematopoietic stem cell transplantation (HSCT) in SAVI, a condition associated with severe morbidity, progressive lung failure, and limited treatment options.
The findings challenge previous concerns that HSCT might fail because variant STING is also expressed in non-hematopoietic tissues such as endothelial and lung epithelial cells. Instead, the study demonstrates that correcting the hematopoietic
immune compartment alone can substantially suppress systemic disease activity.
The report also suggests that:
· Earlier transplantation may prevent irreversible fibrosis.
· Certain high-risk genotypes (such as p.N154S) may warrant earlier HSCT consideration.
· HSCT could potentially become a curative strategy for other interferonopathies and autoinflammatory disorders resistant to conventional therapies.
Hope for the Future
The case provides hope that children with severe SAVI may one day achieve long-term remission or cure through immune system replacement rather than lifelong partial suppression with medications.
The authors suggest that future international registries and prospective studies may help refine:
· optimal timing of transplantation,
· conditioning regimens,
· long-term monitoring strategies, and
· patient selection criteria.
The study also raises the possibility that HSCT or future gene-based therapies could benefit patients with related interferon-driven diseases such as coatomer protein complex alpha (COPA syndrome, chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperatures (CANDLE) syndrome, and familial chilblain lupus.
Read More:
Background
STING-associated vasculopathy with onset in infancy (SAVI) is a rare autosomal dominant monogenic interferonopathy caused by gain-of-function mutations in TMEM173, the gene encoding STING. Constitutive STING activation results in chronic type I interferon and NF-κB pathway activation, driving systemic autoinflammation. Clinical manifestations include early-onset vasculitic skin ulceration, recurrent fevers, interstitial lung disease (ILD), pulmonary fibrosis, and failure to thrive.
Current therapies such as corticosteroids and Janus kinase (JAK) inhibitors—including ruxolitinib, tofacitinib, and baricitinib—may partially suppress interferon signalling but frequently fail to prevent progressive organ damage.
The authors report a 6-year-old boy carrying a heterozygous de novo TMEM173 p.N154S mutation, a genotype associated with aggressive disease. Despite sequential treatment with multiple JAK inhibitors and antifibrotic therapy, the patient developed worsening pulmonary fibrosis and persistent cutaneous vasculopathy.
Given the refractory nature of the disease, the patient underwent fully HLA-matched sibling allogeneic hematopoietic stem cell transplantation (allo-HSCT) after myeloablative conditioning. The rationale was that replacing the dysregulated hematopoietic immune compartment might extinguish the chronic interferon-driven inflammatory cascade.
What the Study Found
The patient achieved rapid donor engraftment following allo-HSCT, with neutrophil recovery by day +14, platelet engraftment by day +21, and >99% donor chimerism by day +30. No acute graft-versus-host disease (GVHD) or major peri-transplant infections occurred.
Clinically, the transplant produced substantial disease improvement:
· Complete healing of chronic vasculitic skin ulcers by 6 months post-HSCT, maintained at 12 months.
· Progressive normalization of inflammatory biomarkers including erythrocyte sedimentation rate (ESR) and cytokines relevant to interferon mediated inflammation including interleukin (IL)-6 by 9–12 months post-transplant.
· Stabilization of interstitial lung disease with no new fibrotic progression on serial chest computed tomography (CT) imaging.
· Significant pulmonary function improvement, with forced expiratory volume in 1 second (FEV1) increasing from 70.1% predicted pre-HSCT to 102.4% predicted at 12 months.
· Restoration of adaptive and humoral immunity, including recovery of CD4+ and CD8+ T-cell subsets, B cells, plasma cells, and normalization of IgG and IgA levels.
Immunologically, the findings support the hypothesis that hematopoietic-derived immune cells are major drivers of SAVI pathology. Despite persistent mutant STING expression in non-hematopoietic tissues, immune replacement alone was sufficient to suppress systemic interferon-mediated inflammation.
The patient experienced one transient episode of autoimmune haemolytic anaemia (AIHA), which resolved with corticosteroid treatment.
Citation Yu et al., Mol Therapy: Advances 2026 Mar 34:1-7.
Authors
Yu U, Song A, Luo C, Luo C, Qin X, Huang X, Wang X, Lin Y, Zhou C, Zhang M, Chen J, Wang X.
Date of publication 1/3/2026 Link 10.1016/j.omta.2026.201699